- Home
- GLPG vs DNLI Comparison
GLPG vs DNLI Comparison
Compare GLPG & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- DNLI
- Stock Information
- Founded
- GLPG 1999
- DNLI 2013
- Country
- GLPG Belgium
- DNLI United States
- Employees
- GLPG N/A
- DNLI N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLPG Health Care
- DNLI Health Care
- Exchange
- GLPG Nasdaq
- DNLI Nasdaq
- Market Cap
- GLPG 1.8B
- DNLI 2.1B
- IPO Year
- GLPG 2005
- DNLI 2017
- Fundamental
- Price
- GLPG $24.77
- DNLI $12.29
- Analyst Decision
- GLPG Sell
- DNLI Strong Buy
- Analyst Count
- GLPG 5
- DNLI 16
- Target Price
- GLPG $26.75
- DNLI $37.57
- AVG Volume (30 Days)
- GLPG 159.3K
- DNLI 1.3M
- Earning Date
- GLPG 04-23-2025
- DNLI 05-06-2025
- Dividend Yield
- GLPG N/A
- DNLI N/A
- EPS Growth
- GLPG N/A
- DNLI N/A
- EPS
- GLPG 1.16
- DNLI N/A
- Revenue
- GLPG $285,380,474.00
- DNLI N/A
- Revenue This Year
- GLPG $0.08
- DNLI N/A
- Revenue Next Year
- GLPG $0.23
- DNLI $373.37
- P/E Ratio
- GLPG $21.58
- DNLI N/A
- Revenue Growth
- GLPG 14.99
- DNLI N/A
- 52 Week Low
- GLPG $22.36
- DNLI $12.05
- 52 Week High
- GLPG $32.17
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- GLPG 38.92
- DNLI 29.24
- Support Level
- GLPG $24.48
- DNLI $13.67
- Resistance Level
- GLPG $25.72
- DNLI $14.84
- Average True Range (ATR)
- GLPG 0.51
- DNLI 0.81
- MACD
- GLPG -0.15
- DNLI 0.03
- Stochastic Oscillator
- GLPG 14.15
- DNLI 5.84
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.